Skip to main content
Equibles

DIADEMA PARTNERS LP

Position in SMMT — Summit Therapeutics Inc.

CIK 2026172 MORRISTOWN, NJ
Back to SMMT Full portfolio

Position in SMMT

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$874,200
+$874,200 QoQ
Shares Held
60,000
Ownership
0.008%
of shares outstanding
% of Portfolio
0.33%
of 13F equity value
Holder Rank
#94
of 242 holders
Holding Since
Dec 2024
5 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in SMMT Over Time

Shares Held

Position Value (USD)

Derivatives in SMMT

reported options exposure · as of Jun 30, 2026
CallValue
$12,533,114
CallShares
860,200
PutValue
$2,914,000
PutShares
200,000

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

DIADEMA PARTNERS LP holds $217,374,297 across 66 Biotechnology names. SMMT ranks #43 (0.4% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 RVMD
Revolution Medicines, Inc.
 139,218 $26,072,747
2 ABVX
Abivax S.A.
 163,644 $21,807,199
3 COGT
Cogent Biosciences, Inc.
 493,664 $19,104,796
4 BMRN
Biomarin Pharmaceutical Inc
 312,846 $17,901,048
5 VKTX
Viking Therapeutics, Inc.
 441,808 $17,234,930
6 EWTX
Edgewise Therapeutics, Inc.
 272,214 $11,060,054
7 KOD
Kodiak Sciences Inc.
 218,117 $8,497,838
8 IMCR
Immunocore Holdings plc
 254,863 $8,091,900

All Filings in SMMT

Export CSV
10 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $2,914,000 200,000
2026-06-30 $12,533,114 860,200
2026-06-30 $874,200 60,000
2025-09-30 $1,543,302 74,700
2025-06-30 $19,832 932
2025-06-30 $1,589,616 74,700
2025-06-30 $1,064,000 50,000
2025-03-31 $476,463 24,700
2024-12-31 $356,900 20,000
2024-12-31 $151,682 8,500